Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women
The objective of the study is to evaluate the effects of Angeliq on BP over a period of 8
weeks in postmenopausal women who may benefit from hormone replacement therapy (HRT) for the
relief of vasomotor symptoms and who have hypertension.
Safety/Efficacy Study of Drospirenone/Estradiol to Treat Postmenopausal Chinese Women With Vasomotor Symptoms.
The study evaluates in Chinese post-menopausal women the combination of drospirenone 2 mg
and estradiol 1 mg for the treatment of climacteric symptoms, such as hot flushes (vasomotor
symptoms) and uro-genital complaints.
Treatment of Vasomotor Symptoms in Korean Post Menopausal Women
Study to demonstrate that the therapeutic efficacy of Angeliq® is better than placebo in
Korean postmenopausal women with hot flushes and other climacteric symptoms. Safety and
tolerability of Angeliq.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.